Zydus Lifesciences Expands into Europe with Strategic Orthopedic Play

has taken a strategic step toward strengthening its presence in the global medtech space by establishing a new subsidiary in France. The newly formed entity, Zydus MedTech (France) SAS, was incorporated on April 10, 2025, and will serve as the vehicle for acquiring a majority stake in the French orthopedic firm Amplitude Surgical SA. The subsidiary was set up with an authorised capital of €1,000, of which €100 is paid-up capital, and the remaining €900 accounted as issuance premium. This structure reflects the early-stage investment framework intended for executing the acquisition. As per previously disclosed terms, Zydus Lifesciences, through this new entity, will acquire 85.6% equity in Amplitude Surgical at €6.25 per share, aggregating to a transaction value of €256.8 million. Following the block acquisition, a mandatory tender offer is planned for the remaining stake at the same price, with the intent to delist the company through a squeeze-out mechanism, subject to regulatory conditions. This move aligns with Zydus’ broader global strategy of diversifying into high-value healthcare segments and tapping growth markets outside India. The expansion into orthopedics through a European foothold signals the company’s long-term commitment to scaling its international medtech portfolio. Further updates on the deal’s closure and integration will follow as the process advances. Disclaimer: Investing involves risks. Please review all relevant information before making decisions. Past performance does not guarantee future results. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.